FDA Approves AbbVie's Novel Parkinson's Disease Medication, Juvmo

AbbVie has secured FDA approval for Juvmo, a new once-daily medication for Parkinson's disease. This treatment is notable as the first FDA-approved Parkinson's therapy to selectively activate D1/D5 dopamine receptors, offering a novel approach to managing symptoms such as stiffness, tremors, and movement difficulties for patients.